LegoChem Biosciences

21 articles about LegoChem Biosciences

• Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing

  2/7/2024

  Samsung Biologics today announced it has signed a partnership agreement with LegoChem Biosciences (KOSDAQ: 141080), a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs.

• 

  Pan Orion Invests $415M in Korean Biotech LegoChem, Secures Majority Stake

  1/16/2024

  The snacks and confectionery giant has been seeking to enter the biopharmaceuticals space in recent years.

• LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC

  12/26/2023

  LegoChem Biosciences, Inc. announced on December 22 that it has entered into a license agreement with Janssen Biotech, Inc., a Johnson & Johnson company, to develop and commercialize LCB84, a Trop2 directed antibody drug conjugate.

• CORRECTING and REPLACING LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC

  12/26/2023

  LegoChem Biosciences, Inc. announced on December 22 that it has entered into a license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize LCB84, a Trop2 directed antibody drug conjugate (ADC).

• LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial

  11/7/2023

  BostonGene and LegoChem Biosciences, Inc. announced a collaboration to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers.

• LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development

  10/16/2023

  LegoChem Biosciences Inc. and Glycotope GmbH have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies, building on a previously announced 2022 collaboration and license agreement.

• LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera

  2/13/2023

  LegoChem Biosciences Inc. announced on February 13, 2023 a license agreement with Elthera AG, a biotechnology company in Switzerland, to develop and commercialize a novel antibody-drug conjugate therapy using a monoclonal antibody developed by Elthera.

• LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates

  12/23/2022

  LCB Grants Amgen Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Amgen with LCB’s Proprietary ADC Platform.

• NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates

  11/15/2022

  NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets.

• LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate

  7/12/2022

  LegoChem Biosciences Inc. and Glycotope GmbH have signed a Research Collaboration and License Agreement to develop an antibody drug conjugate by combining LCB's proprietary ADC technology with one of Glycotope's investigational tumor targeting antibodies.

• Iksuda Therapeutics Deepens Clinical Pipeline Through Licensing Agreement for Her2 Antibody Drug Conjugate Programme From LegoChem Biosciences

  1/10/2022

  Iksuda Therapeutics announced further expansion of its differentiated ADC pipeline through a license and commercialisation agreement with LegoChem Biosciences, a Korean biopharmaceutical company focused on the development of next-generation novel therapeutics utilising its proprietary medicinal drug discovery technologies.

• Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates

  10/21/2021

  Antengene Corporation Limited announced that it has entered into a Research Collaboration and License Option Agreement with LegoChem Biosciences, Inc. for new antibody-drug conjugates.

• LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates

  6/22/2021

  Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates with raised therapeutic index, announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc. to explore additional ADC programmes which leverage LCB’s proprietary ADC platform technology.

• LegoChem Biosciences and Iksuda Enter Licensing Agreement for Antibody Drug Conjugate Program

  5/15/2020

  LegoChem Biosciences, Inc. (“LCB”) (KOSDAQ:141080), based in Daejeon, South Korea, announced today a worldwide license agreement with Iksuda Therapeutics (“Iksuda”) for the development and commercialization of LCB73, a CD19-targeted ADC candidate for hematological tumors. Under the terms of the agreement, Iksuda will make an upfront payment of USD 5 million and LCB is eligible to receive development, regulator

• LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates

  4/16/2020

  LegoChem Biosciences, Inc. (“LCB”) (KOSDAQ:141080), based in Daejeon, South Korea, announced today that it has entered a research collaboration and license agreement with Iksuda Therapeutics (“Iksuda”) for the development of antibody-drug conjugates in oncology.

• LegoChem Biosciences and Takeda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates in Immuno-Oncology

  3/22/2019

  Takeda gains certain rights to LCB’s antibody-drug conjugate technology, ConjuAll, including LCB’s proprietary linker and conjugation platform, to research, develop and commercialize targeted immuno-oncology therapeutics.

• Geom Therapeutics To Develop And Commercialize LegoChem Biosciences' Novel Beta Lactamase Inhibitors For Treating Gram-Negative Infections

  9/27/2017

• LegoChem Biosciences Receives U.S. Patent For Its Own Proprietary ADC Platform Technology ConjuAll

  4/17/2017

• RMX Acquires China Rights To Novel Antibiotic From LegoChem Biosciences

  1/20/2017

• LegoChem Biosciences Enters Into Research Licensing Agreement With Takeda To Develop Next-Generation Antibody-Drug Conjugate Candidates

  1/11/2017